Granted Patent
B2
US 12,359,174 · App. 17/408,104 · Granted Jul 15, 2025
Methods of predicting ancestral virus sequences and uses thereof
C12N7/00A61K39/00C07K14/00C07K14/005C07K16/22C12N15/86A61K2039/525A61K2039/6075C07K2317/24C07K2317/76C12N2750/14121C12N2750/14122C12N2750/14123C12N2750/14141C12N2750/14142C12N2750/14143C12N2750/14171
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods are described for predicting ancestral sequences for viruses or portions thereof. Also described are predicted ancestral sequences for adeno-associated virus (AAV) capsid polypeptides. The disclosure also provides methods of gene transfer and methods of vaccinating subjects by administering a target antigen operably linked to the AAV capsid polypeptides.
Claims (13)
1. A method comprising:
administering to a subject in need thereof a plurality of recombinant adeno-associated virus (rAAV) particles, wherein each rAAV particle comprises an AAV capsid polypeptide and a transgene, wherein the AAV capsid polypeptide comprises an amino acid sequence chosen from: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, and 17, and the transgene is within the rAAV particle.
2. The method of claim 1 , wherein the method is a method of vaccinating the subject.
3. The method of claim 1 , wherein the method is a method of delivering a gene therapy to the subject.
4. The method of claim 1 , wherein the AAV capsid polypeptide exhibits less seroprevalence than an AAV2 capsid polypeptide and/or about the same or less seroprevalence than an AAV8 capsid polypeptide.
5. The method of claim 1 , wherein the AAV capsid polypeptide is neutralized to a lesser extent by human serum than an AAV2 capsid polypeptide, and wherein the AAV capsid polypeptide is neutralized to a similar or lesser extent by human serum than an AAV8 capsid polypeptide.
6. The method of claim 1 , wherein the AAV capsid polypeptide has the sequence of SEQ ID NO: 1.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 1 , wherein the plurality of rAAV particles are in a composition further comprising a carrier.
9. The method of claim 1 , wherein the plurality of rAAV particles transduces or infects cells in the subject.
10. The method of claim 9 , wherein the cells are ear cells.
11. The method of claim 10 , wherein the ear cells are inner ear cells.
12. The method of claim 4 , wherein the subject has a lower titer of antibodies that are capable of neutralizing the AAV capsid polypeptide than the titer of antibodies capable of neutralizing an AAV2 or AAV8 capsid polypeptide.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 27, 2021
From: VANDENBERGHE, LUK H.
To: MASSACHUSETTS EYE & EAR INFIRMARY
Reel/Frame 057603/0370 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 27, 2021
From: ZINN, ERIC
To: SCHEPENS EYE RESEARCH INSTITUTE
Reel/Frame 057603/0562 →
Continuity (9)
Continuation In Part
PCTUS2014060163
· Oct 10, 2014
Provisional Application
61889827
· Oct 11, 2013
References Cited (142)
US 5037384A
· Chang
· 1991
[cited by applicant]
US 5817075A
· Giungo
· 1998
[cited by applicant]
US 7906111B2
· Wilson et al.
· 2011
[cited by applicant]
US 9782232B1
· Papac
· 2017
[cited by applicant]
US 20010014788A1
· Morris
· 2001
[cited by applicant]
US 20020106729A1
· Bleck
· 2002
[cited by applicant]
US 20070225727A1
· Matsuhisa et al.
· 2007
[cited by applicant]
US 20090226531A1
· Lyons et al.
· 2009
[cited by applicant]
US 20110098536A1
· Corcosteugi et al.
· 2011
[cited by applicant]
US 20120093772A1
· Horsager et al.
· 2012
[cited by applicant]
US 20130095071A1
· Bance
· 2013
[cited by examiner]
US 20150182756A1
· Peyman
· 2015
[cited by applicant]
US 20160296221A1
· Morris
· 2016
[cited by applicant]
CA 2193802
· 1996
[cited by applicant]
CN 1826414
· 2006
[cited by applicant]
JP 2007500518
· 2007
[cited by applicant]
WO WO2003089612
· 2003
[cited by applicant]
WO WO2005033321
· 2005
[cited by applicant]
WO WO2006110689
· 2006
[cited by applicant]
WO WO2006110689A3
· 2007
[cited by applicant]
WO WO2010136549
· 2010
[cited by applicant]
WO WO2014160092
· 2014
[cited by applicant]
WO WO2015054653
· 2015
[cited by applicant]
WO WO2018119330
· 2018
[cited by applicant]
WO WO2020069461
· 2020
[cited by applicant]
WO WO2021154923
· 2021
[cited by applicant]
WO WO2022150634
· 2022
[cited by applicant]
Office Action in Australian Appln. No. 2021290371, dated Jan. 16, 2023, 6 pages.
[cited by applicant]
GenBank Accession No. ACB55317, “capsid protein VP1, partial (endogenous virus) [Adeno-associated virus],” dated Jul. 31, 2008, 2 pages.
[cited by applicant]
Office Action in Chinese Appln. No. 201680057177.2, dated Oct. 9, 2022, 12 pages (with English translation).
[cited by applicant]
Extended European Search Report in European Appln. No. 22182170.5, dated Jan. 4, 2023, 11 pages.
[cited by applicant]
[No Author Listed], “American Society of Gene & Cell Therapy 17th Annual Meeting,” Molecular Therapy, May 1, 2014, 22(Supplement 1): S1-S305.
[cited by applicant]
Adachi et al., “MOLPHY: Programs for Molecular Phylogenetics based on Maximum Likelihood,” Tokyo Institute of Statistical Mathematics, 1996, ed.
[cited by applicant]
Altschul et al., “Gapped BLAST and PSI-BLAST: A new generation of protein database search programs,” Nucleic Acids Res., 1997, 25(17):3389-3402.
[cited by applicant]
Anisimova et al., “Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative,” Systematic Biology, 2006, 55:539-52.
[cited by applicant]
AU Office Action in Australian Appln. No. 2019201986, dated Mar. 13, 2020, 7 pages.
[cited by applicant]
Balazs et al., “Antibody-based protection against HIV infection by vectored immunoprophylaxis,” Nature, 2012, 481:81-4.
[cited by applicant]
Balazs et al., “Broad protection against influenza infection by vectored immunoprophylaxis in mice,” Nat. Biotechnol., 2013, 31:647-52.
[cited by applicant]
Bartel et al., “Directed evolution of novel adeno-associated viruses for therapeutic gene delivery,” Gene Therapy, Mar. 2012, 19: 694-700.
[cited by applicant]
Boutin et al., “Prevalence of serum IgG and neutralizing factors against AAV types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV vectors,” Hum. Gene Ther., 2010, 21:704-12.
[cited by applicant]
CA Office Action in Canadian Application No. 2,927,077, dated Jul. 2, 2020, 3 pages.
[cited by applicant]
Calcedo et al. “Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses,” J. Infect. Dis., 2009, 199:381-90.
[cited by applicant]
Cao et al., “Phylogenetic relationships among eutherian orders estimated from inferred sequences of mitochondrial proteins: instability of a tree based on a single gene,” J. Mol. Evol., 1994, 39:519-27.
[cited by applicant]
Carvalho et al., “Abstract #: 120: Retinal Tropism of In Silico Reconstructed Ancestral Adeno-Associated Viruses,” Molecular Therapy, May 2014, 22(Supplement 1): S45.
[cited by applicant]
Darriba et al., “ProTest3: Fast selection of best-fit models of protein evolution,” Bioinformatics, 2011, 27(8):1164-5.
[cited by applicant]
Dayhoff et al., “22: A model of evolutionary change in proteins,” Atlas of protein sequence and structure, vol. 5, National Biomedical Research Foundation Silver Spring, 1978, pp. 345-352.
[cited by applicant]
Deal et al., “Vectored antibody gene delivery protects against plasmodium falciparum sporozoite challenge in mice,” PNAS USA, 2014, 111:12528-32.
[cited by applicant]
EBI Accession No. GSP:ANJ81137, “Adeno-associated viral capsid protein, AAV-8,” Dec. 13, 2007.
[cited by applicant]
Edgar, “Muscle: A multipole sequence alignment method with reduced time and space complexity,” BMC Bioinform., 2004, 5:113.
[cited by applicant]
EP European Search Report in Application No. 16790158.6, dated Jan. 3, 2019, 5 pages.
[cited by applicant]
EP European Search Report in Application No. 18190809.6, dated Dec. 19, 2018, 5 pages.
[cited by applicant]
EP Extended European Search Report in Application No. 16831443.3, dated Nov. 26, 2018, 20 pages.
[cited by applicant]
Eyewiki.aao.org [online], “Pars Plana Vitrectomy,” Nov. 20, 2019, retrieved on Mar. 27, 2020, retrieved from URL<https://eyewiki.aao.org/Pars_Plana_Vitrectomy>, 7 pages.
[cited by applicant]
Felsenstein, “Maximum Likelihood and Minimum-Steps Methods for Estimating Evolutionary Trees from Data on Discrete Characters,” Systematic Biology, 1973, 22:240-9.
[cited by applicant]
Fisher et al., “Recombinant adeno-associated virus for muscle directed gene therapy,” 1997, Nature Med., 3:306-12.
[cited by applicant]
Gao et al., “Adeno-associated viruses undergo substantial evolution in primates during natural infections,” PNAS, 2003, 100:6081-6.
[cited by applicant]
Gao et al., “Clades of Adeno-associated viruses are widely disseminated in human tissues,” J. Virol., 2004, 78:6381-88.
[cited by applicant]
Gao et al., “New recombinant serotypes of AAV vectors,” Current Gene Ther., 2005, 5:285-97.
[cited by applicant]
Gascuel, “BioNJ: An improved version of the NJ algorithm based on a simple model of sequence data,” Mol. Biol. Evol., 1997, 14:685-95.
[cited by applicant]
GenBank Accession No. AAC03780.1, “major coat protein VP1 [Adeno-associated virus—2],” Feb. 24, 1998, 1 page.
[cited by applicant]
GenBank Accession No. AAD13756.1, “capsid protein [Adeno-associated virus—5],” Feb. 10, 1999, 1 page.
[cited by applicant]
GenBank Accession No. AAD27757.1, “capsid protein [Adeno-associated virus—1],” Apr. 27, 1999, 1 page.
[cited by applicant]
GenBank Accession No. AAN03857.1, “capsid protein [Adeno-associated virus—8],” Sep. 2, 2002, 1 page.
[cited by applicant]
GenBank Accession No. AAO88201.1, “capsid protein [Non-human primate Adeno-associated virus],” Apr. 9, 2003, 1 page.
[cited by applicant]
GenBank Accession No. AAS99264.1, “capsid protein VP1 [Adeno-associated virus 9],” May 25, 2004, 1 page.
[cited by applicant]
GenBank Accession No. EU368910.1, “Adeno-associated virus isolate AAV6.2 capsid protein VP1 gene, partial cds,” Jul. 31, 2008, 1 page.
[cited by applicant]
GenBank Accession No. EU368925.1, “Adeno-associated virus isolate rh.8R capsid protein VP1 gene, partial cds,” dated Jul. 31, 2008, 2 pages.
[cited by applicant]
GenBank Accession No. EU368926, “Adeno-associated virus isolate rh32.33 capsid protein VP1 gene, partial cds,” Jul. 31, 2008, 1 page.
[cited by applicant]
Guindon et al., “A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood,” Systematic Biology, 2003, 52:696-704.
[cited by applicant]
Henikoff at al., “Amino acid substitution matrices from protein blocks,” PNAS, 1992, 89:10915-9.
[cited by applicant]
IN Office Action in Indian Appln. No. 201637014659, dated May 28, 2020, 8 pages.
[cited by applicant]
Jones et al., “The rapid generation of mutation data matrices from protein sequences,” Comp. Appl. Biosci., 1992, 8:275-82.
[cited by applicant]
JP Office Action in Japanese Application No. 2018-504699 dated Jun. 9, 2020, 6 pages (with English translation).
[cited by applicant]
Katoh et al., “MAFFT version 5: Improvement in accuracy of multiple sequence alignment,” Nuc. Acids Res., 2005, 33:511-8.
[cited by applicant]
Koerber et al., “DNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny,” Molecular Therapy, Aug. 2008, 16: 1703-1709.
[cited by applicant]
Lassmann et al., “Kalign, Kalignvu and Mumsa: Web servers for multiple sequence alignment,” Nuc. Acids Res., 2006, 34:W596-99.
[cited by applicant]
Limberis et al., “Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza,” Sci. Transl. Med., 2013, 5:187ra72.
[cited by applicant]
Lock et al., “Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale,” Hum. Gene Ther., 2010, 21:1259-71.
[cited by applicant]
Loytynoja et al., “An Algorithm for progressive multiple alignment of sequences with insertions,” PNAS USA, 2005, 102:10557-62.
[cited by applicant]
Loytynoja et al., “Phylogeny-Aware Gap Placement Prevents Errors in Sequence Alignment and Evolutionary Analysis,” Science, 2008, 320:1632-5.
[cited by applicant]
Maheshri et al., “Directed evolution of adeno-associated virus yields enhanced gene delivery vectors,” Nature Biotechnology, Jan. 2006, 24: 198-204.
[cited by applicant]
Manning et al., “Transient immunosuppression allows transgene expression following re-administration of adeno-associated viral vectors,” 1998, Human Gene Ther., 9:477-85.
[cited by applicant]
Mao et al., “Persistent Suppression of Ocular Neovascularization with intravitreal administration of AAVrh.10 coding for Bevacizumab,” Hum. Gene Ther., 2011, 22:1525-35.
[cited by applicant]
Nakai et al., “A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction,” J. Virol., 2002, 76:11343-9.
[cited by applicant]
Nakai et al., “Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice,” J. Virol., 2005, 79:214-24.
[cited by applicant]
Ncbi.nlm.nih.gov [online], “Facts and Figures Concerning the Human Retina,” Jul. 5, 2007, retrieved on Mar. 28, 2020, retrieved from URL<https://www.ncbi.nlm.nih.gov/books/NBK11556/>, 6 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2016298394, dated Feb. 25, 2022, 4 pages.
[cited by applicant]
Office Action in Australian Appln. No. 2016298394, dated Mar. 16, 2022, 8 pages.
[cited by applicant]
Office Action in Chinese Appln. No. 201680057177.2, dated Feb. 25, 2022, 13 pages (with English translation).
[cited by applicant]
Paul et al., “Determination of hepatitis E virus seroprevalence by using recombinant fusion proteins and synthetic peptides,” J. Infect. Dis., 1994, 169:801-6.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2016/031218, mailed on Nov. 16, 2017, 7 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Application No. PCT/US2016/044819, mailed on Feb. 8, 2018, 5 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2014/060163, mailed on Jul. 13, 2015, 19 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2016/031218, mailed on Aug. 8, 2016, 12 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Application No. PCT/US2016/044819, mailed on Oct. 31, 2016, 5 pages.
[cited by applicant]
Reeves, “Heterogeneity in the substitution process of amino acid sites of proteins coded for by mitochondrial DNA,” 1992, J. Mol. Evol., 35:17-31.
[cited by applicant]
Sakhria et al., “Co-Circulation of Toscana Virus and Punique Virus in Northern Tunisia: A microneutralisation-based seroprevalence study,” PLOS Negl. Trop. Dis., 2013, 7:e2429.
[cited by applicant]
Santiago-Ortiz et al., “AAV ancestral reconstruction library enables selection of broadly infectious viral variants,” Gene Therapy, Jul. 2015, 22: 934-946.
[cited by applicant]
Sarkar et al., Abstract #: 194: “Seroprevalence Assessment of Novel, Ancestrally Derived AAV Vectors,” Molecular Therapy, May 2014, 22(Supplement 1): S74.
[cited by applicant]
Sauerbrei et al. “Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006,” Euro Survell., 2011,16(44):3).
[cited by applicant]
Schneider et al., “Empirical codon substitution matrix,” BMC Bioinform., 2005, 6:134.
[cited by applicant]
Schon et al., “Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications,” European Journal of Pharmaceutics and Biopharmaceutics, Jan. 2015, 95: 343-352.
[cited by applicant]
Schuster et al., “Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse,” Frontiers in Neuroanatomy, Jun. 2014, 8: 42 (14 pages).
[cited by applicant]
Schwarz, “Estimating the Dimension of a Model,” Ann. Statist. 1978, 6:461-4.
[cited by applicant]
Sen et al., “Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy”, Scientific Reports, May 2013, 3(1):1-6.
[cited by applicant]
Wang et al., “Systematic Evaluation of AAV Vectors for Liver directed Gene Transfer in Murine Models, ” Mol. Ther., 2010, 18:118-25.
[cited by applicant]
Watanabe et al., “AAVrh 10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors,” Gene Ther., 2010, 17:1042-51.
[cited by applicant]
Whelan et al., “A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach,” Mol. Biol. Evol., 2001, 18:691-9.
[cited by applicant]
Xie et al., “AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer,” Gynecol. Oncol, 2014, 135: 325-32.
[cited by applicant]
Xu et al., “Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States,” Am. J. Obstet. Gynecol., 2007, 196:43.e1-6.
[cited by applicant]
Yang, “Maximum-likelihood estimation of phylogeny from DNA sequences when substitution rates differ over sites,” Mol. Biol. Evol., 1993, 10:1396-1401.
[cited by applicant]
Yang, “PAML: A program package for phylogenetic analysis by maximum likelihood,” Comp. Applic. BioSci., 1997, 13:555-6.
[cited by applicant]
Zinn and Vandenberghe, “Adeno-associated virus: fit to serve,” Current Opinion in virology, Oct. 2014, 8: 90-97.
[cited by applicant]
Zinn et al., “Abstract #: 237: In Silico, Ancestral Reconstruction of AAV Particles Circumvents Pre-Existing Immunity in Humans,” Molecular Therapy, May 2014, 22(Supplement 1): S90.
[cited by applicant]
Zinn et al., “In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector,” Cell Rep., Aug. 2015, 12(6):1056-1068.
[cited by applicant]
Notice of Acceptance in Australian Appln. No. 2021290371, dated Jun. 16, 2023, 4 pages.
[cited by applicant]
Notice of Allowance in Japanese Appln. No. 2022-203970, dated Oct. 3, 2023, 6 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 201680057177.2, dated May 31, 2023, 18 pages (with English translation).
[cited by applicant]
Office Action in New Zealand Appln. No. 739476, dated Apr. 18, 2024, 4 pages.
[cited by applicant]
Office Action in New Zealand Appln. No. 778484, dated Apr. 22, 2024, 4 pages.
[cited by applicant]
Notice of Allowance in Japanese Appln. No. 2023-188537, mailed on Nov. 5, 2024, 6 pages (with English translation).
[cited by applicant]
Office Action in Australian Appln. No. 2023226672, dated Sep. 10, 2024, 4 pages.
[cited by applicant]
Office Action in Canadian Appln. No. 3182790, dated Sep. 16, 2024, 5 pages.
[cited by applicant]
Office Action in Chinese Appln. No. 202210398488.2, dated Aug. 8, 2024, 11 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202210398489.7, dated Aug. 8, 2024, 11 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202210398490.X, dated Aug. 9, 2024, 12 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202210398491.4, dated Aug. 8, 2024, 11 pages (with English translation).
[cited by applicant]
Office Action in European Appln. No. 20171389.8, dated May 10, 2024, 5 pages.
[cited by applicant]
Office Action in Chinese Appln. No. 2022103984882, mailed on Dec. 30, 2024, 8 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 2022103984897, mailed on Dec. 30, 2024, 8 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 202210398490X, mailed on Dec. 30, 2024, 8 pages (with English translation).
[cited by applicant]
Office Action in Chinese Appln. No. 2022103984914, mailed on Dec. 30, 2024, 8 pages (with English translation).
[cited by applicant]